; (ii) 20 percent shall become available for obligation during the first fiscal year after the fiscal year during which the distribution is made; (iii) 20 percent shall become available for obligation during the second fiscal year after the fiscal year during which the distribution is made; (iv) 20 percent shall become available for obligation during the third fiscal year after the fiscal year during which the distribution is made; and (v) 20 percent shall become available for obligation during the fourth fiscal year after the fiscal year during which the distribution is made. (B) Availability of amounts Any amounts distributed under paragraph (2) shall remain available until expended. (6) Authorized uses Amounts distributed under paragraph (2) from the Fund shall be used to support— (A) basic research on the underlying basis for disease to better address disease prevention, diagnosis, and treatment; (B) research that fosters disruptive innovation, such as— (i) research on diseases or conditions for which treatments exist but are inadequate, including chronic and acute pain; (ii) research on diseases or conditions for which there are unmet medical needs; (iii) research on diseases or conditions for which treatments exist but the side effect profiles of such treatments limit therapeutic potential; (iv) research on new approaches to treatment of diseases using drugs, devices, or therapies that, at the time of distribution under paragraph (2), are not used or are underused; or (v) research conducted by experienced investigators with a history of productive and innovative research, such that funding provides long-term stability for such research and allows such investigators to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop groundbreaking techniques